Walsh JA, et al. - In patients with psoriatic arthritis (PsA), experts assessed the long-term effectiveness of certolizumab pegol (CZP) treatment with and without concomitant DMARDs. Participants had active PsA with ≥ 1 failed DMARD. Total resolution at week 216 was reported by high proportions of DMARD+/DMARD− patients with extra-articular manifestations at baseline; dactylitis 91.4% of DMARD+ and 93.3% of DMARD− patients, enthesitis 74.4% of DMARD+ and 87.5% of DMARD− patients. In PsA symptoms, long-term improvements across important psoriatic disease domains, including joint disease, psoriasis, nail disease, dactylitis, and enthesitis were observed with CZP monotherapy or concomitant DMARDs.